Ethan Ravotti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ethan Ravotti has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Amy Nolte
School of Engineering, Penn State Behrend, 4701 College Drive, Erie, PA 16563, USA
1 shared publication - Anne M. Gohn
School of Engineering Penn State Erie 4701 College Drive Erie PA 16563 USA
1 shared publication - Gamini Mendis
Pennsylvania State University
1 shared publication - Morgan Giles
Merck & Co., Inc., Rahway, NJ 07033, USA
1 shared publication - Nathan Rudd
Merck & Co., Inc., Rahway, NJ 07033, USA
1 shared publication - Seth P. Forster
Pharmaceutical Commercialization Technology, MMD, Merck & Co., Inc., Kenilworth, NJ 07033, USA
1 shared publication
Latest Publications
- Open Access
- 27 May 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (6) , 1139
Dissolution from Ethylene Vinyl Acetate Copolymer Long-Acting Implants: Effect of Model Active Ingredient Size and Shape
In recent pharmaceutical applications, an active pharmaceutical ingredient (API) can be mixed with a polymer material to yield a composite long-acting drug-delivery device. These devices boast higher patient compliance, localized drug delivery, and lower dosage concentrations, which can increase patient safety. As a laboratory-safe option, calcium carbonate (CaCO3) was used as a drug surrogate to mimic the release kinetics of a low-solubility API. The release of CaCO3 from a poly(ethylene vinyl acetate) (EVA) polymer matrix was studied in ultra-high-purity water. The geometry of CaCO3, along with the manufacturing technique, was manipulated to study the implications on surrogate drug release. It was found that injection molding proved to yield higher burst release, due to higher pressures achievable during manufacturing. The extrusion process can affect the surface concentration of the pharmaceutical ingredient when extruded through a water bath, resulting in a lower initial burst concentration. Regarding CaCO3 geometry, the particle size was more critical than the surface area in terms of CaCO3 release. Larger particles showed a higher release rate, though they also displayed higher variability in release. These data can be used to engineer specific release profiles when designing composite formulations and manufacturing methods for pharmaceutical-drug-delivery applications.
- 27 May 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (6) , 1139
Open AccessDissolution from Ethylene Vinyl Acetate Copolymer Long-Acting Implants: Effect of Model Active Ingredient Size and Shape
In recent pharmaceutical applications, an active pharmaceutical ingredient (API) can be mixed with a polymer material to yield a composite long-acting drug-delivery device. These devices boast higher patient compliance, localized drug delivery, and lower dosage concentrations, which can increase patient safety. As a laboratory-safe option, calcium carbonate (CaCO3) was used as a drug surrogate to mimic the release kinetics of a low-solubility API. The release of CaCO3 from a poly(ethylene vinyl acetate) (EVA) polymer matrix was studied in ultra-high-purity water. The geometry of CaCO3, along with the manufacturing technique, was manipulated to study the implications on surrogate drug release. It was found that injection molding proved to yield higher burst release, due to higher pressures achievable during manufacturing. The extrusion process can affect the surface concentration of the pharmaceutical ingredient when extruded through a water bath, resulting in a lower initial burst concentration. Regarding CaCO3 geometry, the particle size was more critical than the surface area in terms of CaCO3 release. Larger particles showed a higher release rate, though they also displayed higher variability in release. These data can be used to engineer specific release profiles when designing composite formulations and manufacturing methods for pharmaceutical-drug-delivery applications.